Cyclerion Therapeutics

Update in progress

CYCN (NasdaqCM)

Company RatingNeutral
SectorHealthcare
IndustryBiotechnology

Cyclerion Therapeutics is a biopharmaceutical company developing treatments for serious diseases using novel soluble guanylate cyclase (sGC) stimulators in the central nervous system and periphery. It is advancing Olinciguat, an oral sGC stimulator in Phase 2 for cardiovascular diseases, and Praliciguat, a systemic sGC stimulator for rare kidney disease. It licenses Praliciguat and related products from Akebia. Founded 2018, based in Cambridge, MA.

Company score

Sentiment: 0.32; SentimentMeasures the overall tone of recent coverage and discussion about the company.−10 negative · 0 neutral · +10 positive
Environment: 0.00; EnvironmentAssesses the company’s environmental impact, risks, and sustainability practices.−10 negative · 0 neutral · +10 positive
Social: 0.26; SocialAssesses the company’s influence on employees, customers, communities, and wider society.−10 negative · 0 neutral · +10 positive
Governance: 0.10; GovernanceAssesses leadership, accountability, transparency, and business ethics.−10 negative · 0 neutral · +10 positive
Sustainability: 0.10; SustainabilityCombines environmental, social, and governance signals into an overall sustainability score.−10 negative · 0 neutral · +10 positive
Impact Score: 0.21; Impact ScoreCombines sentiment and sustainability performance into an assessment of the company’s overall impact.−10 negative · 0 neutral · +10 positive